KR970707096A - 평활근 이완 활성을 갖는 N-아릴 및 N-헤테로아릴-1,2-디아미노사이클로부텐-3,4-디온(N-Aryl and N-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities) - Google Patents

평활근 이완 활성을 갖는 N-아릴 및 N-헤테로아릴-1,2-디아미노사이클로부텐-3,4-디온(N-Aryl and N-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities)

Info

Publication number
KR970707096A
KR970707096A KR1019970702911A KR19970702911A KR970707096A KR 970707096 A KR970707096 A KR 970707096A KR 1019970702911 A KR1019970702911 A KR 1019970702911A KR 19970702911 A KR19970702911 A KR 19970702911A KR 970707096 A KR970707096 A KR 970707096A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
perfluoroalkyl
compound according
carbon atoms
Prior art date
Application number
KR1019970702911A
Other languages
English (en)
Inventor
존 안토니 부테라
슈일러 아담 안타네
브래드포드 하몬드 허쓰
Original Assignee
슬레이터 티모시 티
아메리칸 홈 프로덕츠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 슬레이터 티모시 티, 아메리칸 홈 프로덕츠 코포레이션 filed Critical 슬레이터 티모시 티
Publication of KR970707096A publication Critical patent/KR970707096A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

화학식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
상기 식에서, R1은 수소, C1-10직쇄 또는 측쇄 알킬, C3-10사이클릭 또는 비사이클릭 알킬, 탄소수 2 내지 7의 알카노일, 탄소수 1 내지 7의 알킬설포닐, 탄소수 7 내지 12의 아로일, 탄소수 9 내지 20의 아릴알케노일, 탄소수 6 내지 12의 아릴설포닐, 탄소수 8 내지 12의 아릴알카노일 또는 탄소수 7 내지12의 아릴알킬설포닐이고; R2는 수소, C1-10직쇄 또는 측쇄 알킬 또는 C3-10사이클릭 또는 비사이클릭 알킬이며; A는 그룹(여기서, R7및 R8은 서로 독립적으로, 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노, 설폰아미드, C1-6알킬설폰아미도, C6-12아릴설폰아미도, C2-6알킬카복스아미도, C7-12아릴카복스아미도, C1-6알킬설포닐, C1-6퍼플루오로알킬설포닐, C6-12아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실, 탄소수 2 내지 7의 카복알콕시, 하이드록실 또는 수소이다)이거나, A는 Het는
(여기서, R9는 수소, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노, C1-6알킬설폰아미도, C2-6알킬카복스아미도, 니트로, 시아노, 카복실, 클로로, 브로모, 플루오로 또는 요오도이다)로부터 선택된다]이며; n은 0 내지 6의 정수이고; R3및 R4는 서로 독립적으로, 수소, C1-10직쇄 또는 측쇄 알킬 또는 C3-10사이클릭 또는 비사이클릭 알킬; C1-10퍼플루오로알킬, C1-10하이드록시알킬, C2-10알콕시알킬, 플루오로; 또는 함께 총 탄소수 3 내지 7의 스피로사이클릭 환을 형성하고; R5및 R6는 서로 독립적으로, 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노, 설폰아미드, C1-6알킬설폰아미도, C6-12아릴설폰아미도, C2-6알킬카복스아미도, C7-12아릴카복스아미도, C1-6알킬설포닐, C1-6퍼플루오로알킬설포닐, C6-12아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실, C2-7카보알콕시, 하이드록실 또는 수소이다.

Description

평활근 이완 활성을 갖는 N-아릴 및 N-헤테로아릴-1,2-디아미노사이클로부텐-3,4-디온(N-Aryl and N-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (22)

  1. 하기 화학식(Ⅰ)의 화합물 및 이의 약제학적으로 허용되는 염.
    상기 식에서, R1은 수소, C1-10직쇄 또는 측쇄 알킬, C3-10사이클릭 또는 비사이클릭 알킬, 탄소수 2 내지 7의 알카노일, 탄소수 1 내지 7의 알킬설포닐, 탄소수 7 내지 12의 아로일, 탄소수 9 내지 20의 아릴알케노일, 탄소수 6 내지 12의 아릴설포닐, 탄소수 8 내지 12의 아릴알카노일 또는 탄소수 7 내지 12의 아릴알킬설포닐이고; R2는 수소, C1-10직쇄 또는 측쇄 알킬 또는 C3-10사이클릭 또는 비사이클릭 알킬이며; A는 그룹(여기서, R7및 R8은 서로 독립적으로, 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노, 설폰아미드, C1-6알킬설폰아미도, C6-12아릴설폰아미도, C2-6알킬카복스아미도, C7-12아릴카복스아미도, C1-6알킬설포닐, C1-6퍼플루오로알킬설포닐, C6-12아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실, 탄소수 2 내지 7의 카보알콕시, 하이드록실 또는 수소로부터 선택된다)이거나, A는 Het[이때, Het는
    (여기서, R9는 수소, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노,C1-6알킬설폰아미도, C2-6알킬카복스아미도, 니트로, 시아노, 카복실, 클로로, 브로모, 플루오로, 요오도이다)로부터 선택된다]이며; n은 0 내지 6의 정수이고; R3및 R4는 서로 독립적으로, 수소, C1-10직쇄 또는 측쇄 알킬 또는 C3-10사이클릭 또는 비사이클릭 알킬; C1-10퍼플루오로알킬, C1-10하이드록시알킬, C2-10알콕시알킬, 플루오로; 또는 탄소수 3 내지 7의 스피로사이클릭 환을 형성하고; R5및 R6는 서로 독립적으로, 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼를루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노, 설폰아미드, C6-12알킬설폰아미도, C6-12아릴설폰아미도, C2-6알킬카복스아미도, C7-12아릴카복스아미도, C1-6아킬설포닐, C1-6퍼플루오로알킬설포닐, C6-12아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸리, 카복실, C2-7카보알콕시, 하이드록실 또는 수소이다.
  2. 제1항에 있어서, A가 화학식(여기서, R7및 R8은 서로 독립적으로, 시아노, 니트로, 아미노, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실 및 수소로부터 선택된다)의 그룹이거나; A는 Het[여기서, Het는
    (이때, R9는 상기 정의한 바와 같다)로부터 선택된다]이며; n은 0이고; R3및 R4는 서로 독립적으로, 수소, C1-10직쇄 또는 측쇄 알킬, C1-10퍼플루오로알킬, C1-10하이드록시알킬 또는 플루오로이며; R5및 R6는 서로 독립적으로, 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, 클로로, 브로모, 플루오로, 요오도, 카복실, C2-7카보알콕시, 하이드록실 또는 수소로부터 선택된 화합물 및 이의약제학적으로 허용되는 염.
  3. 제1항에 있어서, 4-[3,4-디옥소-2-(1-페닐-에틸아미노)-사이클로부트-1-에닐아미노]-벤조니트릴인 화합물.
  4. 제1항에 있어서, 3-(5-브로모-피리딘-3-일아미노)-4-(1-페닐-에틸아미노)-사이클로부트-3-엔-1,2-디온인 화합물.
  5. 제1항에 있어서, 3-(2-메톡시-5-트리플루오로메틸-페닐아미노)-4-(1-페닐-에틸아미노)-사이클로부트-3-엔-1,2-디온인 화합물.
  6. 제1항에 있어서, 3-(1-페닐-에틸아미노)-4-(피리딘-4-일아미노)-사이클로부트-3-엔-1,2-디온인 화합물.
  7. 제1항에 있어서, 3-(4-트리플루오로메톡시-페닐아미노)-4-(1-페닐-에틸아미노)-사이클로부트-3-엔-1,2-디온인 화합물.
  8. 제1항에 있어서, 4-{2-[1-(4-니트로-페닐)-에틸아미노]-3,4-디옥소-시아클로부트-1-에닐아미노}-벤조니트릴인 화합물.
  9. 제1항에 있어서, 3-[3,4-디옥소-2-(1-페닐-에틸아미노)-사이클로부트-1-에닐아니노]-벤조니트릴인 화합물.
  10. 제1항에 있어서, 4-[3,4-디옥소-2-(1-메틸-1-페닐-에틸아미노)-사이클로부트-1-에닐아미노]-벤조니트릴인 화합물.
  11. 제1항에 있어서, 4-[3,4-디옥소-2-(1-페닐-프로필아미노)-사이클로부트-1-에닐아미노]-벤조니트릴인 화합물.
  12. 제1항에 있어서, 4-[3,4-디옥소-2-(벤질아미노)-사이클로부트-1-에닐아미노]-벤조니트릴인 화합물.
  13. 제1항에 있어서, 4-{2-[1-(4-메틸-페닐)-에틸아미노]-3,4-디옥소-사이클로부트-1-에닐아미노}-벤조니트릴인 화합물.
  14. 제1항에 있어서, 4-{2-[1-(4-메톡시-페닐)-에틸아미노]-3,4-디옥소-사이클로부트-1-에닐아미노}-벤조니트릴인 화합물.
  15. 제1항에 있어서, 4-{3,4-디옥소-2-[1-(4-트리플루오로메톡시페닐)-에틸아미노]-사이클로부트-1-에닐아미노}-벤조니트릴인 화합물.
  16. 제1항에 있어서, 4-[3,4-디옥소-2-(2,2,2-트리플루오로-1-페닐-에틸아미노)-사이클로부트-1-에닐아미노]-벤조니트릴인 화합물.
  17. 제1항에 있어서, 4-[3,4-디옥소-2-(1-페닐-에틸아미노)-사이클로부트-1-에닐아미노]-3-메틸-벤조니트릴인 화합물.
  18. 제1항에 있어서, 4-[3,4-디옥소-2-(1-페닐-에틸아미노)-사이클로부트-1-에닐아미노]-3-에틸-벤조니트릴인 화합물.
  19. 제1항에 있어서, N-(4-시아노-페닐)-N-[3,4-디옥소-2-(1-페닐-에틸아미노)-사이클로부트-1-에닐]-아세트아미드인 화합물.
  20. 평활근 수축의 반(反)작용을 감소시킬 필요가 있는 환자에게 화학식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염을 경구 또는 비경구투여함을 포함하여, 평활근 수축의 반작용을 감소시키는 방법:
    상기 식에서, R1은 수소, C1-10직쇄 또는 측쇄 알킬, C3-10사이클릭 또는 비사이클릭 알킬, 탄소수 2 내지 7의 알카노일, 탄소수 1 내지 7의 알킬설포닐, 탄소수 7 내지 12의 아로일, 탄소수 9 내지 20의 아릴알케노일, 탄소수 6 내지 12의 아릴설포닐, 탄소수 8 내지 12의 아릴알카노일 또는 탄소수 7 내지 12의 아릴알킬설포닐이고; R2는 수소, C1-10직쇄 또는 측쇄 알킬 또는 C3-10사이클릭 또는 비사이클릭 알킬이며; A는 그룹(여기서, R7및 R8은 서로 독립적으로, 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노, 설폰아미드, C1-6알킬설폰아미도, C6-12아릴설폰아미도, C2-6알킬카복스아미도, C7-12아릴카복스아미도, C1-6아킬설포닐, C1-6퍼플루오로알킬설포닐, C6-12아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실, 탄소수 2 내지 7의 카보알콕시, 하이드록실 또는 수소이다)이거나, A는 Het[이때, Het는
    (여기서, R9는 수소, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노, C1-6알킬설폰아미도, C2-6알킬카복스아미도, 니트로, 시아노, 카복실, 클로로, 브로모, 플루오로 또는 요오도이다)로부터 선택된다]이며; n은 0 내지 6의 정수이고; R3및 R4는 서로 독립적으로, 수소, C1-10직쇄 또는 측쇄 알킬 또는 C3-10사이클릭 또는 비사이클릭 알킬; C1-10퍼플루오로알킬, C1-10하이드록시알킬, C2-10알콕시알킬, 플루오로; 또는 함께 총 탄소수 3 내지 7의 스피로사이클릭 환을 형성하고; R5및 R6는 서로 독립적으로, 시아노, 니트로, 아미노, C1-6알킬, C1-6퍼플루오로알킬, C1-6알콕시, C1-6퍼플루오로알콕시, 아미노, C1-12모노- 또는 디알킬아미노, 설폰아미드, C1-6알킬설폰아미도, C6-12아릴설폰아미도, C2-6알킬카복스아미도, C7-12아릴카복스아미도, C1-6알킬설포닐, C1-6퍼플루오로알킬설포닐, C6-12아릴설포닐, 클로로, 브로모, 플루오로, 요오도, 1-이미다졸릴, 카복실, C2-7카보알콕시, 하이드록실 또는 수소로부터 선택된다.
  21. 제20항에 있어서, 평활근이 역으로 수축하여 뇨실금을 유발하는 방법.
  22. 제20항에 있어서, 평활근이 역으로 수축하여 과민성 대장 증후군을 유발하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702911A 1994-11-04 1995-10-25 평활근 이완 활성을 갖는 N-아릴 및 N-헤테로아릴-1,2-디아미노사이클로부텐-3,4-디온(N-Aryl and N-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities) KR970707096A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/334,475 US5466712A (en) 1994-11-04 1994-11-04 Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
US08/334475 1994-11-04
PCT/US1995/014597 WO1996014300A1 (en) 1994-11-04 1995-10-25 N-aryl and n-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities

Publications (1)

Publication Number Publication Date
KR970707096A true KR970707096A (ko) 1997-12-01

Family

ID=23307378

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702911A KR970707096A (ko) 1994-11-04 1995-10-25 평활근 이완 활성을 갖는 N-아릴 및 N-헤테로아릴-1,2-디아미노사이클로부텐-3,4-디온(N-Aryl and N-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities)

Country Status (9)

Country Link
US (3) US5466712A (ko)
EP (1) EP0789690A1 (ko)
JP (1) JPH10509703A (ko)
KR (1) KR970707096A (ko)
AU (1) AU714911B2 (ko)
FI (1) FI971853A (ko)
HU (1) HUT77444A (ko)
NZ (1) NZ296442A (ko)
WO (1) WO1996014300A1 (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332859A (en) * 1996-06-17 2000-06-23 American Home Prod pyridinyl, pyrimidinyl or benzofuranyl methylamino substituted cyclobutene-3,4-dione derivatives
US5872139A (en) * 1996-06-17 1999-02-16 American Home Products Corporation Heterocyclymethylamino derivatives of cyclobutene-3,4-diones
US5750574A (en) * 1996-07-17 1998-05-12 American Home Products Corporation Fluorinated N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5846999A (en) * 1996-07-17 1998-12-08 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5780505A (en) * 1996-07-17 1998-07-14 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones
JP2000513729A (ja) * 1996-07-17 2000-10-17 アメリカン・ホーム・プロダクツ・コーポレイション シクロブテン―３，４―ジオンの置換ｎ―アリールメチルアミノ誘導体
US5763474A (en) * 1996-07-17 1998-06-09 American Home Products Corporation Substituted N-arylmethylamino derivatives of cyclobutene-3,4-diones
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
JP2001526194A (ja) 1997-12-19 2001-12-18 ターロ ファーマシューティカルズ ユーエスエイ インコーポレイテッド 局所的カルバマゼピン製剤及び使用方法
US6376555B1 (en) 1998-12-04 2002-04-23 American Home Products Corporation 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
BR0206968A (pt) * 2001-02-02 2004-03-09 Schering Corp Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como antagonistas receptores de quimiocina cxc
US6495576B2 (en) 2001-02-07 2002-12-17 Abbott Laboratories Aminal diones as potassium channel openers
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
CZ20032831A3 (cs) * 2001-04-16 2004-03-17 Schering Corporation 3,4-Disubstituované cyklobuten-1,2-diony
MXPA04003439A (es) * 2001-10-12 2004-07-08 Schering Corp Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc.
US6878709B2 (en) * 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
NZ535314A (en) * 2002-03-18 2007-08-31 Schering Corp Combination treatments for chemokine-mediated diseases
US20030032802A1 (en) * 2002-08-30 2003-02-13 Palovich Michael R. IL8-receptor antagonists
ATE422203T1 (de) * 2002-10-09 2009-02-15 Schering Corp Thiadiazoldioxide und thiadiazoloxide als cxc- und cc-chemokinrezeptor liganden
KR100508992B1 (ko) * 2003-03-31 2005-08-17 한국유나이티드제약 주식회사 쓴 맛을 개선한 클래리스로마이신 경구용 약제 조성물 및 그의 제조 방법
MXPA06007076A (es) * 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
JP4851943B2 (ja) * 2003-12-22 2012-01-11 シェーリング コーポレイション Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド
ES2327840T3 (es) * 2004-12-23 2009-11-04 Gpc Biotech Ag Derivados de acido escuarico con actividad antiproliferativa.
DE102005001053A1 (de) * 2005-01-07 2006-07-20 Merck Patent Gmbh Quadratsäurederivate
AU2006231023A1 (en) * 2005-04-04 2006-10-12 Merck Patent Gmbh Indazole squaric acid derivatives as CHK1-, CHK2- and SGK- inhibitors
EP1912971A2 (en) * 2005-06-29 2008-04-23 Shering Corporation Di-substituted oxadiazoles as cxc-chemokine receptor ligands
JP2009500328A (ja) * 2005-06-29 2009-01-08 シェーリング コーポレイション Ｃｘｃ−ケモカインレセプターリガンドとしての５，６−ジ−置換オキサジアゾロピラジンおよびチアジアゾロピラジン
RU2009103999A (ru) * 2006-07-07 2010-08-20 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы как лиганды схс-хемокиновых рецепторов
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
EP2318369A1 (en) 2008-06-24 2011-05-11 TopoTarget A/S Squaric acid derivatives as inhibitors of the nicotinamide
GEP20237476B (en) 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54150036A (en) * 1978-05-18 1979-11-24 Sharp Corp Lsi device
DE3069889D1 (en) * 1979-01-18 1985-02-14 Ici Plc Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them
US4390701A (en) * 1981-05-18 1983-06-28 Bristol-Myers Company 1-Amino-2-[3-(3-piperidinomethylphenoxy)propylamino]cyclobutene-3,4-dione
JPS60255756A (ja) * 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
GB8924373D0 (en) * 1989-10-30 1989-12-20 Beecham Group Plc Novel compounds
US5168103A (en) * 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
JPH0692915A (ja) * 1992-07-28 1994-04-05 Sumitomo Metal Ind Ltd １，２−ジアミノシクロブテン−３，４−ジオン誘導体及びその用途
GB9312210D0 (en) * 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
CA2130078A1 (en) * 1993-09-16 1995-03-17 Jonas A. Gylys Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
US5354763A (en) * 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones

Also Published As

Publication number Publication date
US5532245A (en) 1996-07-02
FI971853A0 (fi) 1997-04-30
WO1996014300A1 (en) 1996-05-17
US5466712A (en) 1995-11-14
MX9703093A (es) 1997-07-31
AU4106096A (en) 1996-05-31
FI971853A (fi) 1997-07-01
US5605909A (en) 1997-02-25
JPH10509703A (ja) 1998-09-22
HUT77444A (hu) 1998-04-28
AU714911B2 (en) 2000-01-13
NZ296442A (en) 1999-11-29
EP0789690A1 (en) 1997-08-20

Similar Documents

Publication Publication Date Title
KR970707096A (ko) 평활근 이완 활성을 갖는 N-아릴 및 N-헤테로아릴-1,2-디아미노사이클로부텐-3,4-디온(N-Aryl and N-heteroaryl-1,2-diaminocyclobutene-3,4-diones with smooth muscle relaxing activities)
KR960705780A (ko) 평활근 이완제로서의 디아미노사이클로부텐-3.4-디온(Diaminocyclobutene-3.4-diones as smooth muscle relaxants)
AU5501496A (en) Benzimidazole compounds and their use as modulators of the g abaa receptor complex
PE85999A1 (es) Derivados de fenil y aminofenil-alquilsulfonamida y urea
ATE176223T1 (de) Diaminocyclobuten-3,4-dione
EE9700282A (et) Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
KR970707081A (ko) 디아미노사이클로부텐-3, 4-디온(Diaminocyclobutene-3, 4-diones)
IE45556L (en) 2-[n-(cycloalkylmethyl)-n-(phenyl)-amino]-2- imidazoline¹derivatives
DK0648202T3 (da) Substituerede (arylalkylaminobenzyl)aminopropanamidderivater, fremstilling deraf og anvendelse som anti-epileptiske, neurobeskyttende og antidepressive midler
DE69831612D1 (de) Verfahren zu herstellung von 3(2h)pyridazinon-4-substituierte amino-5-chloro derivate
DE69732359D1 (de) Disubstituierte morpholin-, oxazepin- oder thiazepinderivate, deren herstellung und verwendung als dopamin-d4-rezeptorantagonisten

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application